Table 3.

Main outcomes and adverse events.

Variables	Tocilizumab	Abatacept	Toc vs. Aba
	(8 patients)	(10 patients)	P
Achievement of initial response	8	8	0.18
Time to achieve response to therapy	3.63 (2.66)	3.63 (2.82)	1
Achievement of remission	8 (100%)	5 (50%)	0.019
Time to achieve remission	10.88 (4.39)	11.8 (3.4)	0.3
Flare on therapy	1	2	0.25
Time to first flare on therapy	–	22.5 (9.19)	0.07
Flare out of therapy	0/2	3/3	0.025
Time to first flare out of therapy	–	11 (5.5)
Adverse events
Patients that experience AEs [n (%)]	5 (71.4%)	2 (28.6%)	0.06
Patients that experience SAEs [n (%)]	0	0	–
No. of AEs [mean (SD)]	1 (1.06)	0.2 (0.42)	0.091
Hematological AEs	3 (neutropenia)	0	0.034
Gastrointestinal AEs	0	1 (persistent diarrhea)	0.35
Hepatobiliary AEs	1	0	0.25
Infections	1	0	0.25
Dermatological AEs	0	1

Bold values are significative results.